Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon is attractive because its C1q-first strategy targets the initiating step of the classical complement pathway, offering a differentiated mechanism that may preserve vision and reduce neuroinflammation while potentially avoiding some infection risk seen with broader blockade. The investment case is strengthened by vonaprument’s Phase 3 setup, where enriched enrollment and a 15-month endpoint improve the chance of demonstrating clinically meaningful vision preservation, and the company’s own cited data showed a 73% risk reduction in BCVA 15-letter loss through 12 months in Phase 2. Financially, the recent credit facility and $225M in cash at 1Q26 extend runway into 2028 / 2H27, allowing multiple catalysts from ARCHER II, ANX1502, and tanruprubart to de-risk the story.

Annexon is a high-risk clinical-stage company whose value is heavily dependent on vonaprument’s 4Q26 Phase 3 geographic atrophy readout, yet the Phase 2 ARCHER study missed the primary lesion-growth endpoint and only hinted at vision preservation. The setup is financially fragile as 2Q26 operating expenses were $57M, net loss was $53M, and cash was $209M before a $50M July draw, while the company likely remains loss-making and may need dilutive capital before meaningful commercialization. Competitive and commercial pressures are also severe because GA already has two approved drugs with about $1.1B in combined 2025 sales, and Annexon must prove a differentiated functional benefit in a crowded market while also advancing unproven assets such as tanruprubart and ANX1502.